Pfizer

PFE

Market cap $137B

Overview Fund Activity

24.05 USD

+0.15

0.63%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

24.12

+0.07

0.29%

1 day

0.63%

5 days

-2.24%

1 month

-4.07%

3 months

0.21%

6 months

-7.68%

Year to date

-9.62%

1 year

-19.38%

5 years

-31.15%

10 years

-24.28%

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 81,000

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.79% more ownership

Funds ownership: 64.45% [Q1] → 65.24% (+0.79%) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 1,156 | Existing positions reduced: 1,208

5% less funds holding

Funds holding: 2,889 [Q1] → 2,756 (-133) [Q2]

5% less capital invested

Capital invested by funds: $94.8B [Q1] → $90B (-$4.85B) [Q2]

22% less call options, than puts

Call options by funds: $2.59B | Put options by funds: $3.32B

35% less funds holding in top 10

Funds holding in top 10: 43 [Q1] → 28 (-15) [Q2]

37% less first-time investments, than exits

New positions opened: 142 | Existing positions closed: 226

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

8% upside

Avg. target

$29

21% upside

High target

$33

37% upside

3 analyst ratings

0 positive

0%

3 neutral

100%

0 negative

0%

Citigroup Andrew Baum	$26	Neutral Maintained	6 Aug 2025
Morgan Stanley Terence Flynn	$33	Equal-Weight Maintained	6 Aug 2025
B of A Securities Tim Anderson	$28	Neutral Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 72 articles about PFE published over the past 30 days

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

The Motley Fool

5 Best High-Yield Dividend Stocks to Buy Now

High-yield dividend stocks entice investors with payouts two to four times higher than the S&P 500's 1.4% average yield. But high yield often signals trouble -- sluggish growth, stretched payout ratios, or sector headwinds.

5 Best High-Yield Dividend Stocks to Buy Now

The Motley Fool

3 Things You Need to Know If You Buy Pfizer Today

The S&P 500 is offering a skinny yield of 1.2%. The average healthcare stock has a yield of 1.7%.

3 Things You Need to Know If You Buy Pfizer Today

The Motley Fool

3 Magnificent S&P 500 Dividend Stocks Down as Much as 60% to Buy and Hold Forever

Need investment income? Dividend stocks are an obvious option to consider.

3 Magnificent S&P 500 Dividend Stocks Down as Much as 60% to Buy and Hold Forever

Zacks Investment Research

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

Zacks Investment Research

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

The Motley Fool

1 Reason Every Investor Should Know About Pfizer (PFE) Stock

If you're a long-term investor, why should you be paying closer attention to pharmaceutical giant Pfizer (PFE -3.98%)? Because of its dividend, of course!

1 Reason Every Investor Should Know About Pfizer (PFE) Stock

Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.

Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

See News Rankings

Charts implemented using Lightweight Charts™